EVOKE PHARMA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.48 USD | +1.05% |
|
-1.13% | -54.30% |
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to Evoke Pharma's ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.475
USD
Average target price
7
USD
Spread / Average Target
+1,373.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -54.30% | 4.03M | |
| +32.74% | 695B | |
| +26.51% | 568B | |
| -4.63% | 361B | |
| +19.81% | 330B | |
| +3.68% | 283B | |
| +16.72% | 239B | |
| +8.27% | 204B | |
| -7.98% | 198B | |
| +8.48% | 168B |
- Stock Market
- Equities
- EVOK Stock
- News Evoke Pharma, Inc.
- Transcript : Evoke Pharma, Inc., Q3 2021 Earnings Call, Nov 10, 2021